Navigation Links
New Details Presented at the World Parkinson Congress on Neurologix's Successful Phase 2 Trial of Gene Therapy for Parkinson's Disease
Date:10/1/2010

between the treated and sham groups on the UPDRS Part 3 (Motor section), which has long been the standard for clinical assessment in Parkinson's disease.  All subjects were evaluated at baseline as well as at one, three and six months after undergoing surgery.

The trial also showed that NLX-P101 was well-tolerated with no serious adverse events related to the drug or procedure reported.  All treated subjects will continue to be monitored for safety for a 12-month period following their surgical procedure.

About Parkinson's Disease

Parkinson's disease is a progressive and debilitating neurodegenerative disorder that arises from the gradual deterioration of nerve cells in the brain.  It affects the control of bodily movement and is characterized by four principal symptoms: limb tremor, limb rigidity, bradykinesia (slowness of movement) and postural instability (trouble with balance).  Parkinson's disease is a disease of late middle age, usually affecting people over the age of 50.  According to the National Parkinson Foundation, one million Americans currently have PD, and an estimated 50,000 to 60,000 new cases are diagnosed each year in the United States.  Standard therapy for PD often involves use of levodopa, a drug which stimulates production of dopamine.  Unfortunately, many patients develop complications from dopaminergic interventions.  Alternative treatments include deep brain stimulation, which requires general anesthesia and the implantation of permanent medical devices in the brain.

About Neurologix

Neurologix, Inc., (OTC Bulletin Board: NRGX) is a clinical-stage biotechnology company dedicated to the discovery, development, and commercialization of gene transfer therapies for serious disorders of the brain and CNS.  Neurologix's therapeutic approach is built upon the groundbreakin
'/>"/>

SOURCE Neurologix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. PulmoBioTech Announces Details of Its Regulatory Approval Experiments
2. Pulmo BioTech Announces Details of the Methodology for its Phase I Human Trials
3. Newly Published Article Details How PGS Techniques Directly Effect Successful Pregnancy Outcomes
4. Kendle Announces Details Regarding Third Quarter 2009 Earnings Conference Call and Webcast
5. Young Innovations, Inc. Provides Third Quarter Conference Call Details
6. Cord Blood America Details Las Vegas Laboratory Progress in Analyst Interview
7. Young Innovations, Inc. Provides 4th Quarter Conference Call Details
8. Kendle Announces Details Regarding Second Quarter 2010 Earnings Conference Call and Webcast
9. Young Innovations, Inc. Provides 2nd Quarter Conference Call Details
10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
11. Pre-clinical Data on Recent Advances with HIV VLP Vaccine Presented at AIDS Vaccine 07 Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... 30, 2014 , La ... contribuye a adquirir tolerancia a la proteína de ... proteína de la leche de la vaca (APLV) es la ... Hasta ahora, la APLV se trataba eliminando las ... demostrado que es posible adquirir tolerancia oral en ...
(Date:10/30/2014)... SAN FRANCISCO , Oct. 30, 2014 /PRNewswire/ ... rehydration solution (ORS), announced that it was awarded ... the leading healthcare services company that serves the ... Inc., UHC, Children,s Hospital Association and Provista.  ... designation based on feedback from member hospitals who ...
(Date:10/30/2014)... , Oct. 29, 2014 nebulizer is ... disorders (asthma, COPD and cystic fibrosis) that converts liquid ... easily reach into the lungs of a patient when ... global nebulizers market is dominated by various devices powered ... increasing prevalence of asthma, COPD and cystic fibrosis and ...
Breaking Medicine Technology:Según expertos reunidos en el Simposio Allergy Day 2Según expertos reunidos en el Simposio Allergy Day 3DripDrop Partners With Novation To Help Hospitals Address I.V. Saline Solution Shortages; ORS Product Used For Ebola Outbreak 2DripDrop Partners With Novation To Help Hospitals Address I.V. Saline Solution Shortages; ORS Product Used For Ebola Outbreak 3DripDrop Partners With Novation To Help Hospitals Address I.V. Saline Solution Shortages; ORS Product Used For Ebola Outbreak 4Nebulizers Market (Pneumatic Nebulizers, Ultrasonic Nebulizers and Mesh Nebulizers) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019 2Nebulizers Market (Pneumatic Nebulizers, Ultrasonic Nebulizers and Mesh Nebulizers) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019 3
... 2010 Palatin Technologies, Inc. (NYSE Amex: PTN ... (the "Exchange"), advising Palatin that it is not in compliance ... Section 1003 of the Exchange,s Company Guide. In ... not in compliance with Section 1003(a)(iii) of the Company Guide ...
... 2, 2010 The Harley Medical Group is reporting a ... as an early present for themselves, the month before Christmas. ... to ensure a full recovery is made before they return ... procedures for Christmas 2010 include: Breast enlargement , Nose ...
Cached Medicine Technology:Palatin Technologies Receives Non-Compliance Letter from NYSE Amex 2Palatin Technologies Receives Non-Compliance Letter from NYSE Amex 3The Harley Medical Group Sees an Uptake in Surgery Bookings for Christmas 2
(Date:10/30/2014)... October 30, 2014 Five months after ... Hodgkinson Street LLC announces new branding and a website ... Mepham . After David Mepham’s promotion to name partner ... and website to include Mepham’s name and better reflect ... and mediation firm, the decision to implement new branding ...
(Date:10/30/2014)... Haelle HealthDay Reporter , ... 100 genes have been identified that appear linked to ... researchers say they are on their way to discovering ... the disorder. Autism spectrum disorders include a range ... and repetitive behaviors. An estimated one in 68 U.S. ...
(Date:10/30/2014)... Global prebiotics market is expected to reach ... study by Grand View Research, Inc. Positive outlook on ... fat free products owing to increased concerns over obesity ... the forecast period. , View full report with TOC ... was the largest application segment with market volume of ...
(Date:10/30/2014)... The Woodlands, TX (PRWEB) October 30, 2014 ... hospital system, released today its 2014 third quarter ... hospitals across Texas boasted infection rates of only ... also reported patient satisfaction scores exceeding 98 percent. ... this past quarter, which included rising satisfaction scores,” ...
(Date:10/30/2014)... Dennis Thompson HealthDay Reporter ... lots of milk could be bad for your health, a ... calcium in milk can help strengthen bones and prevent osteoporosis. ... to recommend milk as part of a healthy diet. ... milk did not protect men or women from bone fractures, ...
Breaking Medicine News(10 mins):Health News:Hodgkinson Street Mepham Rebrands 2Health News:Discovery of 100-Plus Genes Tied to Autism May Improve Treatments 2Health News:Discovery of 100-Plus Genes Tied to Autism May Improve Treatments 3Health News:Prebiotics Market Is Expected To Grow At A CAGR Of 9.3% From 2014 To 2020: Grand View Research, Inc. 2Health News:Prebiotics Market Is Expected To Grow At A CAGR Of 9.3% From 2014 To 2020: Grand View Research, Inc. 3Health News:Prebiotics Market Is Expected To Grow At A CAGR Of 9.3% From 2014 To 2020: Grand View Research, Inc. 4Health News:Prebiotics Market Is Expected To Grow At A CAGR Of 9.3% From 2014 To 2020: Grand View Research, Inc. 5Health News:Victory Healthcare Releases Q3 Satisfaction, Infection Rates 2Health News:Victory Healthcare Releases Q3 Satisfaction, Infection Rates 3Health News:Is Milk Your Friend or Foe? 2Health News:Is Milk Your Friend or Foe? 3
... , PITTSBURGH, July 27 Childhood obesity ... adults and can lead to premature death in adulthood due ... In addition to its significant human toll, childhood obesity alone ... , , To address the continued tide ...
... survey of men who opt out of aggressive treatment ... delay treatment for their early prostate cancer are not ... research shows. , The evidence seems to contradict the ... for most patients, according to Dr. Roderick van den ...
... YORK, July 27 Paradigm Spine, LLC, a developer of ... a $21.5 million financing, consisting of a $15mm debt facility ... lender in the $15mm venture debt funding. The $6.5 ... asset management group specializing in high-growth opportunities, and Trevi Health ...
... ... upcoming Materials and Processes for Medical Devices Conference , Aug. 10-12 at the Hilton ... (Vocus) July 27, ... upcoming Materials and Processes for Medical Devices Conference , Aug. 10-12 at the Hilton ...
... , , , ... tell people,s personalities based on the types of drink they enjoy. ... as sweet and indulgent, while someone who likes fruity drinks could be ... Angeles-based BLD & Grace Restaurants says the same could be said for ...
... Spanish . Capsule endoscopy for exploring ... all lesions located by means of conventional colonoscopy. According to ... Medicine the specialised medical journal with greatest international ... achieve similar efficacy to the conventional procedure undertaken with a ...
Cached Medicine News:Health News:Highmark Provides Pediatricians With Resources to Combat Childhood Obesity 2Health News:Highmark Provides Pediatricians With Resources to Combat Childhood Obesity 3Health News:Most Not Worried by Delayed Prostate Cancer Therapy 2Health News:Paradigm Spine Closes $21.5 Million Financing and Announces Promotion of Matt Stuttle to Position of Vice President, US Sales 2Health News:Paradigm Spine Closes $21.5 Million Financing and Announces Promotion of Matt Stuttle to Position of Vice President, US Sales 3Health News:Minnesotans to Keynote Materials for Medical Devices Conference 2Health News:Personality in a Cup 2Health News:Personality in a Cup 3Health News:Colon capsule endoscopy diagnoses 64 percent of total polyps detected by conventional colonoscopy 2Health News:Colon capsule endoscopy diagnoses 64 percent of total polyps detected by conventional colonoscopy 3Health News:Colon capsule endoscopy diagnoses 64 percent of total polyps detected by conventional colonoscopy 4Health News:Colon capsule endoscopy diagnoses 64 percent of total polyps detected by conventional colonoscopy 5
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: